| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Aclaris Therapeutics, Inc. (ACRS) has 6 insiders with recent SEC Form 4 filings, including 6 buys and 9 sells. ACRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 13.95M | $67.80M | - | |
| Other | 510.0K | $2.48M | - | |
| COO | 336.3K | $1.63M | - | |
| CEO | 274.8K | $1.34M | - | |
| Other | 18.7K | $90.9K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 18, 2018 | Ali-Jackson Kamil71 | Chief Legal Officer | Sell | 10,000 | $20.00 | $200,000.00 | -10.8% | |
| May 16, 2018 | Powell Andrew Kenneth William | Director | Buy | 500 | $19.12 | $9,560.00 | New | |
| May 7, 2018 | Ruffo Frank74 | Chief Financial Officer | Buy | 1,250 | $18.22 | $22,775.00 | +0.8% | |
| Apr 6, 2018 | Molineaux Christopher P. | Director | Sell | 2,300 | $16.52 | $37,996.00 | -23.0% | |
| Apr 6, 2018 | Tullman Stephen A. | Director | Buy | 26,700 | $16.54 | $441,618.00 | +20.4% | |
| Apr 6, 2018 | Ruffo Frank74 | Chief Financial Officer | Buy | 1,250 | $16.59 | $20,737.50 | +0.8% | |
| Apr 5, 2018 | Walker Neal85 | President And CEO | Buy | 10,000 | $16.75 | $167,500.00 | +1.1% | |
| Aug 16, 2017 | Schiff Andrew N84 | Director | Buy | 108,601 | $23.02 | $2,499,995.02 | +20.7% | |
| Mar 2, 2017 | Vivo Ventures Vii, LLC | 10% Owner | Sell | 425,000 | $30.82 | $13,098,000.00 | -4.5% | |
| Jan 10, 2017 | Mehra Anand | Director | Sell | 750,000 | $28.25 | $21,188,325.00 | -32.8% |